Hematology-American Society of Hematology Education Program

Article	Citations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	64
Your chemo is no good here: management of high-risk MCL	63
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	56
Neurological manifestations of MGUS	37
On the horizon: upcoming new agents for the management of ITP	36
Anticoagulation at the end of life: whether, when, and how to treat	36
Labor and delivery: DIC, HELLP, preeclampsia	34
Mastocytosis demystified	32
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	31
Inpatient recognition and management of HLH	30
Bispecific antibody therapies	27
Diagnosis and therapeutic decision-making for the neutropenic patient	26
Has PD-1 blockade changed the standard of care for cHL?	25
Recognizing, defining, and managing CAR-T hematologic toxicities	25
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	24
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	24
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	23
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	23
Divergent paths: management of early relapsed follicular lymphoma	22
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	22
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	22
New approaches to tackle cytopenic myelofibrosis	21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	21
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	20
MGCS: where do we stand today?	20

Fitness and frailty in myeloma	19
Optimizing outcomes in secondary AML	19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	19
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	18
Troubleshooting heparin resistance	18
How to recognize and manage COVID-19-associated coagulopathy	18
Selecting initial therapy in CLL	18
How to assess hemostasis in patients with severe liver disease	18
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	18
BV and beyond: how to incorporate novel agents into PTCL management	18
How to manage hemostasis in patients with liver disease during interventions	17
Running interferon interference in treating PV/ET: meeting unmet needs	17
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	17
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	17
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	17
Consumptive coagulopathy in the ICU	17
How to diagnose and manage antiphospholipid syndrome	17
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	17
Hemophilia gene therapy: ushering in a new treatment paradigm?	17
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	17
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	16
Special considerations in GI bleeding in VWD patients	16
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	16
Hematology 2022—what is complete HLA match in 2022?	16
Management of TKI-resistant chronic phase CML	16
Demystifying autoimmune HIT: what it is, when to test, and how to treat	15
Management of limited-stage Hodgkin lymphoma	15
What to use to treat AML: the role of emerging therapies	14
Managing therapy-associated neurotoxicity in children with ALL	14
Management of marginal zone lymphomas	14
Atypical CML: diagnosis and treatment	14
How to manage bleeding disorders in aging patients needing surgery	14
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	14
Thrombosis questions from the inpatient wards	13
Approaches to management of HIT in complex scenarios, including cardiac surgery	13
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	13
Infectious complications and vaccines	13
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	13
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	12
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	12
Transplant in AML with measurable residual disease: proceed or defer?	12
CNS prophylaxis in aggressive B-cell lymphoma	12
When does a PNH clone have clinical significance?	12
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	12
Organ function indications and potential improvements following curative therapy for sickle cell disease	12
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	12
Alloimmunization and hyperhemolysis in sickle cell disease	12
Lower risk but high risk	12
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	11
Cytoreduction for ET and PV: who, what, when, and how?	11

What is the ideal approach—doublet, triplet, or quadruplet(s)?	11
Treatment of VTE in the thrombocytopenic cancer patient	11
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	11
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	11
Thrombocytopenia in pregnancy	11
Pegylated interferon: the who, why, and how	11
What makes a pediatric or young adult patient an appropriate transplant candidate?	11
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	11
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	10
Next-generation therapy for lower-risk MDS	10
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	10
Whom should we treat with novel agents? Specific indications for specific and challenging populations	10
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	10
Clinical manifestations of telomere biology disorders in adults	10
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	10
Ph− ALL: immunotherapy in upfront treatment	10
What else do I need to worry about when treating graft-versus-host disease?	9
Should we use bisphosphonates to treat bone complications in sickle cell disease?	9
Porphyria cutanea tarda: a unique iron-related disorder	9
Managing side effects: guidance for use of immunotherapies in multiple myeloma	9
Novel therapies upon failure of HMA plus venetoclax	9
Sequencing bispecific antibodies and CAR T cells for FL	9
Approach to the patient with suspected hypereosinophilic syndrome	9
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	9
Frontline treatment in CLL: the case for time-limited treatment	9
The role of stem cell transplant (auto and allo) in PTCL and CTCL	9
IV iron formulations and use in adults	9
In 2022, which is preferred: haploidentical or cord transplant?	8
Diamond-Blackfan anemia	8
Immunology 101: fundamental immunology for the practicing hematologist	8
When should we use it? The role of brentuximab vedotin in 2024	8
Warm autoimmune hemolytic anemia and the best treatment strategies	8
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	8
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome	8
Are transplant indications changing for myelofibrosis?	8
The spectrum of Ph-negative disease: CNL and CSF3R-related disorders	8
Treatment of older adult or frail patients with multiple myeloma	8
Barriers to accessing cellular therapy for patients receiving care in community practices	8
von Willebrand disease and heavy menstrual bleeding: when and how to test	8
Luspatercept: a treatment for ineffective erythropoiesis in thalassemia	8
The approach of HMA plus VEN with or without BMT for all patients with AML	8
Management of Fanconi anemia beyond childhood	7
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing	7
Novel platelet products including cold-stored platelets	7
Long-term prophylaxis: what are our options and how to define success?	7
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice	7
New definitions for antiphospholipid syndrome: ready for clinical use?	7
Intravenous iron therapy in pediatrics: who should get it and when is the right time?	7
Amyloid consults do not have to be vexing	7
Sequencing therapy in relapsed DLBCL	7
Diagnosis and clinical management of enzymopathies	7
Psychosocial and financial issues after hematopoietic cell transplantation	7
Risk-stratification in frontline CLL therapy: standard of care	7
Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations	7
Clonal hematopoiesis in frequent whole blood donors	7
Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?	7
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	7
Heparin-induced thrombocytopenia and cardiovascular surgery	6
Using disease-modifying therapies in sickle cell disease	6
The intersection of sickle cell disease, stigma, and pain in Africa	6
The first relapse in multiple myeloma: how to pick the next best thing	6
When to consider inherited marrow failure syndromes in adults	6
Mitigating and managing infection risk in adults treated with CAR T-cell therapy	6
Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas	6
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	6
Renal manifestations of MGUS	6
Diagnosis and clinical management of red cell membrane disorders	6
COVID-19 and thrombosis: searching for evidence	6
New investigational combinations for higher-risk MDS	6
Newborn screening initiatives for sickle cell disease in Africa	6
Multiple myeloma: a paradigm for blending community and academic care	6
MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too	6
Molina JC, Rotz S. Acute lymphoblastic leukemia in young adults: which up-front treatment? Hematology Am Soc Hematol Educ Program. 2023;2023(1):573-580.	6
Clonal evolution in inherited marrow failure syndromes predicts disease progression	6
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia	6
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.	5
Management of hemolytic transfusion reactions	5
Sharing is caring: a network collaborative approach to identify and address barriers in accessing clinical trials in adolescents and young adults with leukemia and lymphoma	5
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease	5
Maintenance strategies for relapse prevention and treatment	5

Sickle cell disease in India: the journey and hope for the future	5
Late complications and long-term care of adult CAR T-cell patients	5
Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line	5
Potential and emerging therapeutics for HHT	5
Epidemiology and treatment of priapism in sickle cell disease	5
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	5
Cryptogenic oozers and bruisers	5
Novel clinical care models for patients with sickle cell disease	5
Acute lymphoblastic leukemia in young adults: which up-front treatment?	5
End-of-life care for people with sickle cell disease: barriers to and facilitators of high-quality care	5
Ph+ ALL in 2022: is there an optimal approach?	5
Challenges to successful outcomes in AYAs with ALL and potential solutions	5
Unexplained arterial thrombosis: approach to diagnosis and treatment	5
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3	5
Transplantation in CML in the TKI era: who, when, and how?	5
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	5
Double-hit lymphoma: optimizing therapy	5
Current use of bispecific antibodies to treat multiple myeloma	5
Platton S, Sivapalaratnam S, Raheja P. Diagnosis and laboratory monitoring of acquired hemophilia A. Hematology Am Soc Hematol Educ Program. 2023;2023(1):11-18.	5
Cellular therapy for multiple myeloma: what's now and what's next	4
High-risk multiple myeloma: how to treat at diagnosis and relapse?	4
Acute GVHD: think before you treat	4
Optimal approach to T-cell ALL	4
Dual-targeted regimens for the frontline treatment of CLL	4
Patient-reported outcomes after CAR T-cell therapy in patients with hematological malignancies	4
How to manage ITP with life-threatening bleeding	4
Sex, lies, and iron deficiency: a call to change ferritin reference ranges	4
The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally	4
Catastrophic antiphospholipid syndrome: a CAPS-tivating hematologic disease	4
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?	4
Quantifying menorrhagia and overview of nonsurgical management of heavy menstrual bleeding	4
Ph+ ALL: new approaches for upfront therapy	4
Givosiran: a targeted treatment for acute intermittent porphyria	4
How immunodeficiency can lead to malignancy	4
AL amyloidosis: untangling new therapies	4
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	4
Inflamed—HLH, MAS, or something else?	3
How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT	3
Through thick and thin: confronting the aggressive cutaneous T-cell lymphomas	3
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	3
Perioperative consultative hematology: can you clear my patient for a procedure?	3
Passive immune therapies: another tool against COVID-19	3
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	3
Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL	3
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	3
Incorporating gonadal health counseling into pediatric care of sickle cell patients	3
Novel approaches to acute graft-versus-host disease prevention	3
Identifying and treating iron deficiency anemia in pregnancy	3
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	3
Mutational screening to improve the transplantation decision-making process in MDS	3
Advances in the management of α-thalassemia major: reasons to be optimistic	3
Allogeneic transplantation for advanced acute leukemia	3
Current use of CAR T cells to treat multiple myeloma	3
Modified T cells as therapeutic agents	3
Iron overload in acquired sideroblastic anemias and MDS: pathophysiology and role of chelation and luspatercept	3
Platelet components and bacterial contamination: hospital perspective 2022	3
Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase δ syndrome	3